U.S. FTC says approves final order settling charges related to DaVita-Renal Ventures deal
June 14 (Reuters) - U.S. Federal Trade Commission::Approved final order settling charges that DaVita Inc’s acquisition of Renal Ventures Management would have been anticompetitive.
Latest Developments forDaVita Inc
Latest Key Developments inHealthcare
- Rhoen-Klinikum: Supervisory Board Comments On Article In Manager Magazin
- Fortis Healthcare To Establish Independent Evaluation Process For Evaluating All Binding Proposals
- Hvivo Says Kym Denny Stepping Down As Chief Executive
- IHH Healthcare Says Issued Non-Binding Letter To Fortis To Infuse Up To INR 40 Bln Into Fortis